Mahamaya Lifesciences Ltd
BSE: 544611
₹185.50
₹2.50
(1.37%)
As on 09-Sep-2026 14:12IST
Market cap
₹434 Cr
Revenue (TTM)
₹264 Cr
P/E Ratio
26.3
P/B Ratio
3.8
Div. Yield
0 %
Quality Score
4/10
Growth Score
8/10
Valuation Score
6/10
Momentum Score
9/10
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
₹13 Cr
-
ROE
34.9 %
-
ROCE
26.2 %
-
Industry P/E
39.81
-
EV/EBITDA
14.3
-
Debt to Equity
1.2
-
Book Value
₹27.8
-
EPS
₹7.3
-
Face value
10
-
Shares outstanding
23,405,000
Years Aggregate
CFO
₹--
EBITDA
₹--
Net Profit
₹--
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Mahamaya Lifesciences
| 0.5 | 9.2 | 8.0 | -- | -- | -- | -- |
|
BSE Commodities
| 8.7 | -1.4 | 3.4 | 10.4 | 13.6 | 8.5 | 13.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Mahamaya Lifesciences
|
185.5 | 434.2 | 264.2 | 12.9 | -- | 34.9 | 26.3 | 3.8 |
| 3,954.7 | 17,787.9 | 5,595.4 | 732.1 | 13.9 | 24 | 24.3 | 5.4 | |
| 263.0 | 3,405.8 | 607.2 | 27.5 | 8.8 | 4 | 123.7 | 4.8 | |
| 1,170.0 | 1,938.0 | 1,202.6 | 135.9 | 12.4 | 11.8 | 13.5 | 1.5 | |
| 982.9 | 4,381.8 | 1,953.4 | 268.0 | 16.0 | 16.6 | 16.3 | 2.7 | |
| 626.8 | 1,816.1 | 2,060.4 | 124.8 | 8.4 | 10.3 | 14.5 | 1.4 | |
| 166.1 | 3,956.4 | 1,519.4 | 12.4 | 4.8 | 3.4 | 319.8 | 5.6 | |
| 204.1 | 3,974.9 | 2,962.0 | 214.0 | 9.4 | 13.5 | 18.6 | 1.8 | |
| 784.8 | 7,080.5 | 5,356.5 | 626.2 | 13.1 | 21.5 | 11.3 | 2.2 | |
| 481.6 | 23,949.0 | 3,244.9 | 579.4 | 19.0 | 17.3 | 41.3 | 6.6 |
Shareholding Pattern
View DetailsNews & Analysis
All NewsNo Review & Analysis are available.
About Mahamaya Lifesciences
--
-
Incorporated
2016
-
Chairman
--
-
Managing Director
Krishnamurthy Ganesan
-
Headquarters
New Delhi, Delhi
-
Website
Looking for more details about Mahamaya Lifesciences Ltd’s IPO? Explore our IPO Details page.
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Mahamaya Lifesciences
What is the current share price of Mahamaya Lifesciences Ltd Today?
The share price of Mahamaya Lifesciences Ltd is ₹185.50 (BSE) as of 09-Sep-2026 14:12 IST. Mahamaya Lifesciences Ltd has given a return of --% in the last 1 years.
What is the current PB & PE ratio of Mahamaya Lifesciences Ltd?
The P/E ratio of Mahamaya Lifesciences Ltd is 26.28 times as on 09-Sep-2026, a 34 discount to its peers’ median range of 39.81 times.
The P/B ratio of Mahamaya Lifesciences Ltd is 3.82 times as on 09-Sep-2026, a 17 discount to its peers’ median range of 4.60 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
0.00 |
0.00 |
2024 |
0.00 |
0.00 |
2023 |
0.00 |
0.00 |
2022 |
0.00 |
0.00 |
2025 |
0.00 |
0.00 |
What is the 52 Week High and Low of Mahamaya Lifesciences Ltd?
The 52-week high and low of Mahamaya Lifesciences Ltd are Rs 205.05 and Rs 111.00 as of 09-Sep-2026.
What is the market cap of Mahamaya Lifesciences Ltd?
Mahamaya Lifesciences Ltd has a market capitalisation of ₹ 434 Cr as on 09-Sep-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Mahamaya Lifesciences Ltd?
Before investing in Mahamaya Lifesciences Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.